News
Phase 2 lung cancer trial with Chinese sites is recruiting
AI-assisted summary Written by WellCareChina with AI assistance and checked against the original article.
A phase 2 study registered on ClinicalTrials.gov and updated on 25 September 2026 is recruiting about 130 patients with non-small cell lung cancer to test an investigational drug given with chemoradiation followed by consolidation immunotherapy. The listed sites include hospitals in Dongguan, Guangzhou and Jinan. The sponsor is Johnson & Johnson Enterprise Innovation Inc. Registry entries describe studies; they are not recommendations.
Read the original article Opens the original source in a new tab.
Copyright and re-use
The original article is the authoritative text. This page carries our own summary and a link back; no part of the original is reproduced here.
Source tier A — open access / public domain; summary and link published here, the original remains authoritative.